title: Estimación de la Relación Costo-Efectividad de las Vacunas Neumocócicas Conjugadas Prevenar-13 y Synflorix®, Utilizadas en Los Programas de Vacunación de Población Infantil Mexicana.
abstract: OBJECTIVE
  To estimate the cost effectiveness associated with the use of pneumococcal conjugated vaccines, Prevenar-13 and Synflorix®, in the Mexican pediatric population.
  
  
  METHODS
  The cost-effectiveness ratio of instrumenting vaccination programs based upon the use of Prevenar-13 and Synflorix® in the Mexican pediatric population was estimated by using a Markov's simulation model. The robustness of the conclusions reached on cost-effectiveness for both vaccines was assayed through an univariate and probabilistic sensitivity analysis that included all of the parameters considered by the model.
  
  
  RESULTS
  Synflorix® was dominant over Prevenar-13 in the cost-utility analysis; the former generated more quality-adjusted life years at a lower cost and with a lower incremental cost-utility ratio. Based on the cost-effective analysis, Prevenar-13 generated more life years gained but at a higher cost. The use of Prevenar-13 originated a higher incremental cost-effectiveness ratio and, therefore, it was not cost-effective as compared with Synflorix®.
  
  
  CONCLUSIONS
  Even though the simulations for Prevenar-13 and Synflorix® revealed both of them to be cost-effective when used to instrument pediatric vaccination campaigns in Mexico, Synflorix® had a better cost-utility/effectiveness profile. In addition, although Prevenar-13 and Synflorix® produced equivalent health outcomes, the overall analysis predicted that Synflorix® would save 360 million Mexican pesos, as compared with Prevenar-13.
authors.affiliation: GlaxoSmithKline Vacunas, Buenos Aires, Argentina. Electronic address: Jorge.A.Gomez@gsk.com.
authors.forename: Jorge A
authors.initials: JA
authors.lastname: Gómez
authors.affiliation: Laboratorio de Microbiología Molecular, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, México.
authors.forename: Alberto
authors.initials: A
authors.lastname: Villaseñor-Sierra
authors.affiliation: Jefatura de Prestaciones Médicas, Instituto Mexicano del Seguro Social, Durango, México.
authors.forename: Gerardo Martínez
authors.initials: GM
authors.lastname: Aguilar
authors.affiliation: GlaxoSmithKline Vacunas, Ciudad de México, México.
authors.forename: Roberto Carreño
authors.initials: RC
authors.lastname: Manjarrez
authors.affiliation: GlaxoSmithKline Vacunas, Ciudad de México, México.
authors.forename: María Y
authors.initials: MY
authors.lastname: Cervantes-Apolinar
mesh_terms: D003362:Cost-Benefit Analysis; D000069443:Heptavalent Pneumococcal Conjugate Vaccine / Q000191:economics* / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D008800:Mexico; D011008:Pneumococcal Infections / Q000191:economics / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000191:economics / Q000627:therapeutic use; D019057:Quality-Adjusted Life Years; D013296:Streptococcus pneumoniae; D014611:Vaccination; D018074:Vaccines, Conjugate
chemical_list: D000069443:Heptavalent Pneumococcal Conjugate Vaccine; C547294:PHiD-CV vaccine; D022242:Pneumococcal Vaccines; D018074:Vaccines, Conjugate
keywords: Cost effectiveness; Mexico; Streptococcus pneumoniae; pediatric population; prevention of pneumococcal disease